Welcome to CDC stacks |
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Can We “Hedge” against the Development of Antiviral Resistance among Pandemic Influenza Viruses?
  • Published Date:
    Jun 30 2009
  • Source:
    PLoS Med. 6(6).
Filetype[PDF-72.35 KB]


No Related Documents.
You May Also Like:
  1. Novel Pandemic Influenza A(H1N1) Viruses Are Potently Inhibited by DAS181, a Sialidase Fusion Protein
    Personal Author:
    Triana-Baltzer, Gallen B.; Gubareva, Larisa V.; Nicholls, John M.; Pearce, Melissa B.; Mishin, Vasiliy P.; Belser, Jessica A.; Chen, Li-Mei; Chan, Renee W. Y.; Chan, Michael C. W.; Hedlund, Maria; Larson, Jeffrey L.; Moss, Ronald B.; Katz, Jacqueline M.; Tumpey, Terrence M.; Fang, Fang;
    Published Date:
    November 06 2009
    Source:
    PLoS One. 2009; 4(11)
    Description:
    BackgroundThe recent emergence of a novel pandemic influenza A(H1N1) strain in humans exemplifies the rapid and unpredictable nature of influenza virus evolution and the need for effective therapeutics and vaccines to control such outbreaks. However,...
    File Type:
    Filetype[PDF - 267.32 KB]
  2. Vaccines and Antiviral Drugs in Pandemic Preparedness
    Personal Author:
    Monto, Arnold S.
    Published Date:
    Jan 2006
    Source:
    Emerg Infect Dis. 12(1):55-60.
    Description:
    While measures such as closing schools and social distancing may slow the effects of pandemic influenza, only vaccines and antiviral drugs are clearly efficacious in preventing infection or treating illness. Unless the pandemic strain closely resembl...
    File Type:
    Filetype[PDF - 76.80 KB]
  3. Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir1
    Personal Author:
    Mishin, Vasiliy P.; Patel, Mira C.; Chesnokov, Anton; De La Cruz, Juan; Nguyen, Ha T.; Lollis, Lori; Hodges, Erin; Jang, Yunho; Barnes, John; Uyeki, Timothy; Davis, Charles T.; Wentworth, David E.; Gubareva, Larisa V.;
    Published Date:
    October 17 2019
    Source:
    Emerg Infect Dis. 25(10):1969-1972
    Description:
    Baloxavir showed broad-spectrum in vitro replication inhibition of 4 types of influenza viruses (90% effective concentration range 1.2-98.3 nmol/L); susceptibility pattern was influenza A ˃ B ˃ C ˃ D. This drug also inhibited influenza A viruses o...
    File Type:
    Filetype[PDF - 700.01 KB]
  4. Inhibition of Neuraminidase Inhibitor-Resistant Influenza Virus by DAS181, a Novel Sialidase Fusion Protein
    Personal Author:
    Triana-Baltzer, Gallen B.; Gubareva, Larisa V.; Klimov, Alexander I.; Wurtman, David F.; Moss, Ronald B.; Hedlund, Maria; Larson, Jeffrey L.; Belshe, Robert B.; Fang, Fang;
    Published Date:
    November 06 2009
    Source:
    PLoS One. 2009; 4(11)
    Description:
    Antiviral drug resistance for influenza therapies remains a concern due to the high prevalence of H1N1 2009 seasonal influenza isolates which display H274Y associated oseltamivir-resistance. Furthermore, the emergence of novel H1N1 raises the potenti...
    File Type:
    Filetype[PDF - 288.85 KB]
  5. H275Y Mutant Pandemic (H1N1) 2009 Virus in Immunocompromised Patients
    Personal Author:
    Renaud, Christian; Boudreault, Alexandre A.; Kuypers, Jane; Lofy, Kathryn H.; Corey, Lawrence; Boeckh, Michael J.; Englund, Janet A.;
    Published Date:
    Apr 2011
    Source:
    Emerg Infect Dis. 17(4):653-660.
    Description:
    Most oseltamivir-resistant pandemic (H1N1) 2009 viruses have been isolated from immunocompromised patients. To describe the clinical features, treatment, outcomes, and virologic data associated with infection from pandemic (H1N1) 2009 virus with H275...
    File Type:
    Filetype[PDF - 420.34 KB]